ArticleJournal of controlled release : official journal of the Controlled Release Society2019
RETRACTED: In vitro and in vivo evaluation of degradation, toxicity, biodistribution, and clearance of silica nanoparticles as a function of size, porosity, density, and composition.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- A nucleic acid regulation strategy under mechanical stress for intervertebral disc degeneration treatment.Bioactive materials · 2026Article
- Advances in Drug Delivery Integrated with Regenerative Medicine: Innovations, Challenges, and Future Frontiers.Pharmaceutics · 2025Review
- Antibiofilm activity of mesoporous silica nanoparticles against the biofilm associated infections.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Pulmonary inhalation for disease treatment: Basic research and clinical translations.Materials today. Bio · 2024Review
- Nanomedicine for Diagnosis and Treatment of Atherosclerosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Toxicity evaluation of silica nanoparticles for delivery applications.Drug delivery and translational research · 2023Review
- Self-oxygenation of engineered living tissues orchestrates osteogenic commitment of mesenchymal stem cells.Biomaterials · 2023Article
- Nanoparticles for cancer therapy: a review of influencing factors and evaluation methods for biosafety.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Review
- Mesoporous silica/organosilica nanoparticles for cancer immunotherapy.Exploration (Beijing, China) · 2023Review
- Neonatal Pharmacokinetics and Biodistribution of Polymeric Nanoparticles and Effect of Surfactant.Pharmaceutics · 2023Article
- Nonviral nanoparticle gene delivery into the CNS for neurological disorders and brain cancer applications.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023Review
- Cefazolin-Loaded Double-Shelled Hollow Mesoporous Silica Nanoparticles/Polycaprolactone Nanofiber Composites: A Delivery Vehicle for Regenerative Purposes.Advanced pharmaceutical bulletin · 2023Article
- Prospect of nanomaterials as antimicrobial and antiviral regimen.AIMS microbiology · 2023Review
- Article
- Short term, low dose alpha-ketoglutarate based polymeric nanoparticles with methotrexate reverse rheumatoid arthritis symptoms in mice and modulate T helper cell responses.Biomaterials science · 2022Article
- Zn-Loaded and Calcium Phosphate-Coated Degradable Silica Nanoparticles Can Effectively Promote Osteogenesis in Human Mesenchymal Stem Cells.Nanomaterials (Basel, Switzerland) · 2022Article
- A toxicological profile of silica nanoparticles.Toxicology research · 2022Review
- Toxicity Assessment of Mesoporous Silica Nanoparticles upon Intravenous Injection in Mice: Implications for Drug Delivery.Pharmaceutics · 2022Article
- LbL Nano-Assemblies: A Versatile Tool for Biomedical and Healthcare Applications.Nanomaterials (Basel, Switzerland) · 2022Review
- Particle uptake driven phagocytosis in macrophages and neutrophils enhances bacterial clearance.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
Corrections and comments
- Retraction · 2023-02-17Concerns/Issues about Data · Error in Data · Investigation by Company/Institution · Original Data and/or Images not Provided and/or not Available · Results Not Reproducible ·
- Retracted
Authors and funding
3 authors.
Funding
Abstract
This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of the corresponding author. Subsequent to the publication of the article Journal of Controlled Release 311–312 (2019) 1–15, in follow up studies in 2021, the corresponding author's lab members noticed significant discrepancies in reproducibility of some of the results reported in this manuscript. A detailed investigation in the lab was launched, and by retrieving the raw data available at the core facility pertaining to this manuscript, the following discrepancies were discovered that provide the basis for this retraction. These discrepancies have been reported to the University of Utah Research Integrity and Compliance Office by the corresponding author. The co-authors have been made aware of these discrepancies and of the decision of the corresponding author to retract. The corresponding author believes that the subject matter of this article, detailed analysis of the degradation of silica nanoparticles as a function of their physicochemical properties in relevant biological media in vitro, and in vivo, is significant. For successful utility of these particles in drug delivery applications their detailed biological fate needs to be examined. The significant discrepancies and lack of reproducibility of the reported data however is very unfortunate and the author hopes that this does not cast a doubt on the need for more detailed examination of the biological fate of silica nanoparticles in the future for their successful application in controlled release. In Vitro Data (Fig. 3) • Actual dissolution reaction volume was 2.5mL (confirmed by reviewing the lab notebook of the first author during the investigation) vs 3.5mL reported in the manuscript. • Sample volume was not used in the calculation to convert Inductively Coupled Plasma Mass Spectrometry (ICPMS) data to mg of silicon retrieved which is needed to calculate % degradation (needed to multiply data by 0.1 due to 0.1mL sample volumes). • Our investigation revealed a 20% “matrix effect with fluids” was communicated by ICPMS core facility person to the first author that was not addressed in the manuscript. • All data is different when calculating % degradation, not just by a factor of 10 due to not calculating for the 100ml sample volume. • Raw data during our investigation after publication, obtained from ICPMS facility, and not noted in the lab notebook, for day 28 of simulated lysosomal fluid (SLF) reveals n=1 and no data points for Stober100. In the manuscript however, error bars are shown for all particles at this time point and for the data for Stober100. Intracellular Degradation (Fig. 5) • Extremely high background with control causing negative % degradation for Disulfide Meso 100 from retrieved ICPMS data from core facility after publication, but manuscript shows ~1.25% degradation. • All other calculated % degradation based on retrieved data from ICPMS facility during the investigation after publication, do not match reported data in the paper. • Paper claims n=6, but raw data received from ICPMS facility during investigation (after publication) is clearly n=3. In Vivo Degradation (Fig. 6) ICPMS data retrieved during the investigation after publication for control mice showed extremely high background, and probably were not used in the calculations reported in this manuscript because it would have led to negative silicon contents for a few samples. Urine ICPMS data from the core facility was not available during investigation after publication, and cannot be retrieved from the first author's lab notebook. Hence its validity cannot be ascertained. There may be other discrepancies in the manuscript that have gone unnoticed. However, the Editor-in-Chief agrees that the above is significant enough to warrant retraction of the manuscript.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.